MEREO BIOPHARMA GROUP PLC Earnings Per Share (Basic)
MEREO BIOPHARMA GROUP PLC (MREO) reported Earnings Per Share (Basic) of -$0.01 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC earnings per share, basic for the quarter ending 2026-06-30 was -$0.01.
- MEREO BIOPHARMA GROUP PLC earnings per share, basic for the quarter ending 2026-03-31 was -$0.01.
- MEREO BIOPHARMA GROUP PLC earnings per share, basic for the quarter ending 2025-12-31 was $0.10, a 6.89% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC earnings per share, basic for the quarter ending 2025-09-30 was -$0.01.
- MEREO BIOPHARMA GROUP PLC earnings per share, basic for fiscal 2025 was -$0.05.
- MEREO BIOPHARMA GROUP PLC earnings per share, basic for fiscal 2024 was -$0.06.
- MEREO BIOPHARMA GROUP PLC earnings per share, basic for fiscal 2023 was -$0.04.
- MEREO BIOPHARMA GROUP PLC earnings per share, basic for fiscal 2022 was -$0.07.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.01 10-Q · filed 2026-08-11 | -$0.02 10-Q · filed 2026-08-11 | $0.08 derived: net income ÷ weighted average shares · filed 2026-08-11 | $0.07 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.01 10-Q · filed 2026-05-12 | $0.09 derived: net income ÷ weighted average shares · filed 2026-08-11 | $0.08 derived: net income ÷ weighted average shares · filed 2026-08-11 | $0.06 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | $0.10 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.09 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.07 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.05 10-K · filed 2026-03-19 |
| 2025-09-30 | -$0.01 10-Q · filed 2025-11-10 | -$0.03 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.04 10-Q · filed 2025-11-10 | $0.06 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.02 10-Q · filed 2026-08-11 | -$0.03 10-Q · filed 2026-08-11 | $0.07 derived: net income ÷ weighted average shares · filed 2026-08-11 | $0.05 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.02 10-Q · filed 2026-05-12 | $0.09 derived: net income ÷ weighted average shares · filed 2026-08-11 | $0.07 derived: net income ÷ weighted average shares · filed 2026-08-11 | $0.05 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2024-12-31 | $0.10 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.08 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.07 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$0.06 10-K · filed 2026-03-19 |
| 2024-09-30 | -$0.02 10-Q · filed 2025-11-10 | -$0.04 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.05 10-Q · filed 2025-11-10 | $0.02 derived: net income ÷ weighted average shares · filed 2026-04-09 |
| 2024-06-30 | -$0.02 10-Q · filed 2025-11-10 | -$0.03 10-Q · filed 2025-08-12 | $0.04 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.03 derived: net income ÷ weighted average shares · filed 2026-04-09 |
| 2024-03-31 | -$0.01 10-Q · filed 2025-05-13 | $0.06 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.05 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.05 derived: net income ÷ weighted average shares · filed 2026-04-09 |
| 2023-12-31 | $0.07 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.06 derived: net income ÷ weighted average shares · filed 2026-04-09 | $0.06 derived: net income ÷ weighted average shares · filed 2026-04-09 | -$0.04 10-K · filed 2025-03-26 |
| 2023-09-30 | -$0.01 10-Q · filed 2024-11-12 | -$0.01 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.03 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | -$0.02 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$0.02 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$0.07 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |